Law Offices of Thomas J. Lamb

  • Free Case Evaluation
  • Mesothelioma & Asbestos Diseases
  • Legal Compensation
  • Asbestos Overview
  • Common Questions
  • About Our Firm

Another Antiangiogenic Failure in Unresectable Mesothelioma

June 20, 2019 By Thomas Lamb

The addition of nintedanib (Ofev) to standard of care pemetrexed (Alimta) plus cisplatin failed to delay disease progression in patients with [ unresectable mesothelioma ], according to phase III results of the LUME-Meso study.

After a median treatment duration of more than 5 months, median progression-free survival was 6.8 months for patients assigned to nintedanib, an oral triple angiokinase inhibitor, compared with 7.0 months for those assigned to placebo (P=0.91), reported Giorgio V. Scagliotti, MD, PhD, of the University of Turin, San Luigi Hospital in Italy, and colleagues.

“Despite promising data from the phase II part of the LUME-Meso study, the primary endpoint (progression-free survival) was not met in the phase III part,” they wrote in the Lancet Respiratory Medicine. “New treatment options are still needed in patients with [ unresectable mesothelioma ].”

In an editorial that accompanied the research, Michele Maio, MD, PhD, and Luana Calabrò, MD, PhD, both of the Center for Immuno-Oncology and the University Hospital of Siena in Italy, noted that the LUME-Meso trial is another in a series of trials over the last decade that have “now failed to demonstrate therapeutic efficacy from the targeting of angiogenesis with anti-vascular endothelial growth factor monoclonal antibodies, as well as with multitargeted small-molecule protein kinase inhibitors.”

[Article continues at original source]


 Mesothelioma, Asbestos, and Legal Compensation: Basic Facts

Asbestos-Mesothelioma Case Evaluation Form
Free.  Confidential.  No Obligation.

Filed Under: Medicine, Mesothelioma Tagged With: malignant mesothelioma, malignant pleural mesothelioma (MPM), mesothelioma treatments

Do I Have A Possible Case?

If you have a possible asbestos disease or mesothelioma lawsuit, you can get a free, confidential, and no obligation case review from asbestos lawyer Tom Lamb.

Main Navigation Menu

  • Who Was Exposed to Asbestos
  • NC Asbestos Exposure Sites
  • Asbestos-Contaminated Talc
  • Asbestos Diseases
  • Legal Compensation
  • Free Case Evaluation
  • Frequently Asked Questions
  • About Our Law Firm
  • Attorney Tom Lamb
  • Collection of Articles
  • Sitemap

Attorney Tom Lamb

TJL@LambLawOffice.com

Phone: 800-426-9535

Lumina Station, Suite 225
1908 Eastwood Road
Wilmington, North Carolina

Please know that you can use our Quick Contact Form to tell us about your case.

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Website

Lamb Law Office

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Disclaimer and Copyright Notices
  • Sitemap

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.